ClinicalTrials.gg
TerminatedNCT04209465MasterKey-01Updated Apr 17, 2025Results posted

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

A Phase 1 interventional study of BDTX-189 in Solid Tumor, sponsored by Black Diamond Therapeutics, Inc.. Terminated at 38 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-17.

Primary conditionnone(registry's first term: Lung Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Lung Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Black Diamond Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The development of BDTX-189 was discontinued by the sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study were to:

  • Find the recommended dose of BDTX-189 that can be given safely to participants
  • Learn more about the side effects of BDTX-189
  • Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK)
  • Determine the preliminary antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations
Read the detailed description

BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found in 1 - 2 % of most solid tumors and enriched in some cancers with a prevalence of about 2 - 7% such as in non-small cell lung cancer, breast cancer, colorectal cancer, bladder cancer, and endometrial cancer. Currently approved HER2 and EGFR directed therapies are not active against the spectrum of allosteric mutations at relevant and tolerated exposure levels.

This Phase 1/2 multi-center, open-label trial was a first-in-human study that evaluated BDTX-189 orally administered daily as a single agent in patients with solid tumors harboring select mutations or alterations. The Phase 1 portion was a dose escalation primarily designed to assess the safety and tolerability of BDTX-189 and to determine a recommended Phase 2 dose (RP2D). Phase 1 focused on patients with a solid tumor and with alterations such as:

  • Allosteric HER2 or HER3 mutation(s)
  • EGFR or HER2 exon 20 insertion mutation(s)
  • HER2 amplified or overexpressing tumors
  • EGFR exon 19 deletion or L858R mutation

Eligible mutations must have been determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.

The Phase 2 portion was not initiated.

02

Conditions studied

  • Solid Tumor

Keywords

  • solid tumor
  • HER2 mutation
  • exon 20 insertion mutation
  • HER2 positive
  • Genes, HER2
  • Genes, erbb2
  • HER2 amplification
  • HER2 overexpression
  • genes, exon 20 insertion
  • lung cancer
  • non-small cell lung cancer
  • breast cancer
  • colon cancer
  • colorectal cancer
  • bladder cancer
  • endometrial cancer
  • gastric cancer
  • biliary tract cancer
03

In context

Lead sponsor

Black Diamond Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • - or cytologically-confirmed locally advanced or solid tumor with documented recurrence or disease progression from standard anticancer therapy in the advanced/metastatic setting
  • No standard therapy available or standard therapy is considered unsuitable or intolerable according to the Investigator and consultation with the Medical Monitor

Phase 1 Only:

  • Solid tumor patients with alterations that may be associated with antitumor activity based on preclinical data for BDTX-189 such as:

    1. Allosteric or HER3 mutation(s)
    2. EGFR or HER2 exon 20 insertion mutation(s)
    3. HER2 amplified or overexpressing tumors
    4. EGFR exon 19 deletion or L858R mutation

Eligible mutations must be determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.

  • Adequate or willing to undergo pretreatment biopsy
  • according to version 1.1

Main Exclusion Criteria:

  • Clinical laboratory values meeting the following criteria within 4 weeks (28 days) prior to baseline:

    1. Serum creatinine ≥1.5 × (ULN) or calculated ≤60 mL/min using Cockcroft-Gault equation
    2. Total ≥1.5 × ULN or ≥3.0 × ULN in the presence of documented Gilbert's syndrome
    3. (AST) or alanine aminotransferase (ALT) ≥2.5 × ULN, or AST or ALT ≥5.0 × ULN in the presence of liver metastases
    4. Hematologic function:

      1. (ANC) ≤1000 cells/μL
      2. ≤8.5 g/dL or 5.28 mmol/L
      3. count ≤75,000/μL
  • Significant cardiovascular disease, including:

    1. Cardiac failure Class III or IV, or (LVEF) \<50% or below the lower limit of the Institution's normal range
    2. Myocardial infarction, severe or unstable angina within 6 months prior to baseline
    3. Significant thrombotic or embolic events within 3 months prior to baseline
    4. History or presence of any uncontrolled cardiovascular disease
    5. Personal or family history of long syndrome
  • findings meeting any of the following criteria:

    1. Evidence of second- or third-degree atrioventricular block
    2. arrhythmia (as determined by the Investigator)
    3. QTcF interval of >470 msec
  • or untreated and/or symptomatic CNS (primary or metastatic)
  • Women who are pregnant or breast-feeding
  • Taking or unable to discontinue proton pump inhibitors within 1 week prior to baseline
  • Known concurrent KRAS mutation
  • Known tumor-harboring resistance mutations including EGFR T790M or C797S mutations or HER2 C805S mutation
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Phase 1 - Dose escalation

    In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations received increasing doses of BDTX-189.

    Drug: BDTX-189

Interventions

  • DrugBDTX-189

    Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.

06

What researchers measure

Primary outcomes

  1. Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)

    Certain toxicities will be considered dose-limiting unless clearly attributable to an extraneous cause, such as underlying disease.

    Time frame: After the first dose of treatment for up to 21 days.

Secondary outcomes

  1. Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189

    Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until 30 days post last dose

  2. Phase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics

    Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.

    Time frame: Multiple time points during Cycles 1-4 (each cycle is 21 days)

  3. Phase 1: Objective Response Rate as a Preliminary Measure of Antitumor Activity

    Objective response is defined as the proportion of participants who achieved a complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.

    Time frame: Assessed until disease progression or death for up to 12 months

  4. Phase 1: Progression-free Survival as a Measure of Antitumor Activity

    Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.

    Time frame: Assessed until disease progression or death for up to 12 months

07

Results

Posted Apr 17, 2025
Limitations and caveats
Study terminated early. Phase 2 was not conducted. Limited data collection was performed for this study.

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD Not FastedDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDPhase 1 Safety Expansion
Started11121018137646517
Completed0000023100101
Not completed11121016106645516
Withdrew: Adverse event0000010010211
Withdrew: Death10002722111010
Withdrew: Physician decision0100000000000
Withdrew: Progressive disease0012853413210
Withdrew: Withdrawal by subject0000012010022
Withdrew: Lost to follow-up0000010010010
Withdrew: Started new therapy0000010000000
Withdrew: Study terminated early by sponsor0000003000003
Withdrew: Other0000000010000

Outcome measures

PrimaryNumber of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)

Certain toxicities will be considered dose-limiting unless clearly attributable to an extraneous cause, such as underlying disease.

Time frame:
After the first dose of treatment for up to 21 days.
Reported as:
Number · participants
Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)
participants25 mg QD50 mg QD100 mg QD200 mg QD400 mg QD800 mg QD Fasted800 mg QD Not Fasted1000 mg QD1200 mg QD400 mg BID600 mg BID800 mg BIDSafety Expansion Set 800 mg QD
Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)0000001220331
SecondaryPhase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189

Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.

Time frame:
From Cycle 1 Day 1 (each cycle is 21 days) until 30 days post last dose
Reported as:
Count of participants · Participants
Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189
Participants25 mg QD50 mg QD100 mg QD200 mg QD400 mg QD800 mg QD Fasted800 mg QD Not Fasted1000 mg QD1200 mg QD400 mg BID600 mg BID800 mg BIDSafety Expansion Set 800 mg QD
Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-18900021018137646517
SecondaryPhase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics

Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.

Time frame:
Multiple time points during Cycles 1-4 (each cycle is 21 days)
Reported as:
Geometric mean · Nanogram per mililiter (ng/mL)
Phase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics
Nanogram per mililiter (ng/mL)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QD
Phase 1: Plasma Concentration of BDTX-189 as a Measure of PharmacokineticsNA ± NANA ± NANA ± NA151 ± 67.5170 ± 104268 ± 72.7341 ± 46.40 ± 0352 ± 77.8123 ± 13384.5 ± 39165 ± 53.8248 ± 77.8
SecondaryPhase 1: Objective Response Rate as a Preliminary Measure of Antitumor Activity

Objective response is defined as the proportion of participants who achieved a complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.

Time frame:
Assessed until disease progression or death for up to 12 months
Reported as:
Count of participants · Participants
Phase 1: Objective Response Rate as a Preliminary Measure of Antitumor Activity
ParticipantsDose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QD
Complete response (CR)0000001000000
Partial response (PR)0000021010000
Stable disease (SD)0110493012417
Non-complete response/non-partial response (non-CR/non-PR)0000002100000
Progressive disease (PD)1002645321238
Not evaluable (NE)0000031321012
SecondaryPhase 1: Progression-free Survival as a Measure of Antitumor Activity

Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.

Time frame:
Assessed until disease progression or death for up to 12 months
Reported as:
Mean · Months
Phase 1: Progression-free Survival as a Measure of Antitumor Activity
MonthsDose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QD
Phase 1: Progression-free Survival as a Measure of Antitumor Activity0 (0 to 0)0 (0 to 0)0 (0 to 0)1.61 (0.941 to 2.279)1.866 (0.909 to 2.115)2.306 (0.493 to 4.143)5.158 (0.502 to 11.122)1.416 (1.147 to 2.189)1.572 (0.429 to 2.819)1.508 (0.688 to 2.327)2.252 (1.434 to 3.482)1.354 (0.548 to 2.160)1.772 (1.428 to 3.592)

Adverse events

Collected over Patients remained on-study (on-treatment) until progression, adverse event, or withdrawal of consent. Mean duration of treatment across all dose levels was 11.7 months (median was 6.6 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation 25 mg QD1/1 (100%)0/1 (0%)1/1 (100%)
Dose Escalation 50 mg QD0/1 (0%)0/1 (0%)1/1 (100%)
Dose Escalation 100 mg QD0/1 (0%)0/1 (0%)1/1 (100%)
Dose Escalation 200 mg QD0/2 (0%)2/2 (100%)2/2 (100%)
Dose Escalation 400 mg QD2/10 (20%)2/10 (20%)10/10 (100%)
Dose Escalation 800 mg QD7/18 (38.9%)8/18 (44.4%)18/18 (100%)
Dose Escalation 800 mg QD NF2/13 (15.4%)1/13 (7.7%)13/13 (100%)
Dose Escalation 1000 mg QD2/7 (28.6%)1/7 (14.3%)7/7 (100%)
Dose Escalation 1200 mg QD1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Dose Escalation 400 mg BID1/4 (25%)1/4 (25%)4/4 (100%)
Dose Escalation 600 mg BID1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Dose Escalation 800 mg BID0/5 (0%)3/5 (60%)5/5 (100%)
Safety Expansion 800 mg QD10/17 (58.8%)4/17 (23.5%)17/17 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventDose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QD
pneumoniaInfections and infestations0/10/10/11/21/100/180/130/71/60/41/60/50/17
Anorectal infectionInfections and infestations0/10/10/11/20/100/180/130/70/60/40/60/50/17
PneumonitisRespiratory, thoracic and mediastinal disorders0/10/10/10/20/100/180/130/70/61/41/60/50/17
Acute kidney injuryRenal and urinary disorders0/10/10/10/20/100/180/131/70/60/40/61/50/17
Pleural effusionRespiratory, thoracic and mediastinal disorders0/10/10/10/20/100/180/130/70/60/41/61/50/17
AnemiaBlood and lymphatic system disorders0/10/10/10/20/100/180/130/70/60/40/61/50/17
Cardiac tamponadeCardiac disorders0/10/10/10/20/100/180/130/70/60/40/61/50/17
Pericardial effusionCardiac disorders0/10/10/10/20/100/180/130/70/60/40/61/50/17
Large intestinal hemorrhageGastrointestinal disorders0/10/10/10/20/100/180/130/70/60/40/61/50/17
Abdominal painGastrointestinal disorders0/10/10/10/20/100/180/130/71/60/40/60/50/17
Most frequent other events
Showing 10 of 81
Most frequent other events
EventDose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QD
DiarrheaGastrointestinal disorders0/10/10/10/25/1012/189/135/74/64/45/65/512/17
Decreased appetiteMetabolism and nutrition disorders1/11/10/10/22/105/181/132/70/62/41/62/53/17
Back painMusculoskeletal and connective tissue disorders1/10/11/10/21/103/182/131/70/61/40/60/50/17
ArthralgiaMusculoskeletal and connective tissue disorders0/11/10/10/22/102/181/130/70/60/41/60/52/17
Pain in extremityMusculoskeletal and connective tissue disorders0/11/11/10/20/101/181/130/70/61/41/60/51/17
DyspneaRespiratory, thoracic and mediastinal disorders1/10/10/11/22/101/184/130/71/60/40/60/51/17
HaemoptysisRespiratory, thoracic and mediastinal disorders1/10/10/10/20/100/180/130/70/60/40/60/50/17
VomitingGastrointestinal disorders0/10/10/10/24/109/184/134/75/62/43/63/59/17
NauseaGastrointestinal disorders0/10/10/10/24/1010/188/134/73/63/44/63/510/17
Blood bilirubin increasedInvestigations0/10/10/10/20/101/181/135/71/60/41/62/52/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QDTotal
<=18 years00000000000000
Between 18 and 65 years1011491046045752
>=65 years0101693304201039
Age, Continuous
Age, Continuous(years)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QDTotal
Mean56655160 ± 17.064.5 ± 9.4865.4 ± 11.9460.2 ± 7.0061.4 ± 7.0055.8 ± 6.5971.0 ± 6.0659.3 ± 11.9958.0 ± 5.7065.3 ± 10.3463.1 ± 10.26
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QDTotal
Female010159946353854
Male101159430112937
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QDTotal
Hispanic or Latino000012102010512
Not Hispanic or Latino111291511644451174
Unknown or Not Reported00000111001015
Region of Enrollment
Region of Enrollment(participants)Dose Escalation 25 mg QDDose Escalation 50 mg QDDose Escalation 100 mg QDDose Escalation 200 mg QDDose Escalation 400 mg QDDose Escalation 800 mg QDDose Escalation 800 mg QD NFDose Escalation 1000 mg QDDose Escalation 1200 mg QDDose Escalation 400 mg BIDDose Escalation 600 mg BIDDose Escalation 800 mg BIDSafety Expansion 800 mg QDTotal
United States1112101813764651286
Spain00000000000055
08

Study locations

38 sites
  • 9250
    Scottsdale, Arizona 85258, United States
  • 9405
    Long Beach, California 90813, United States
  • 9474
    Orange, California 92868, United States
  • 7141
    New Haven, Connecticut 06520, United States
  • 4080
    Lake Mary, Florida 32746, United States
  • 4100
    Orlando, Florida 32827, United States
  • 9535
    Plantation, Florida 33322, United States
  • 4060
    Sarasota, Florida 34232, United States
  • 9035
    Atlanta, Georgia 30322, United States
  • 9530
    Rolling Meadows, Illinois 60008, United States
  • 9092
    New Orleans, Louisiana 70112, United States
  • 9203
    Boston, Massachusetts 02215, United States
  • 9209
    Buffalo, New York 14263, United States
  • 9215
    New York, New York 10016, United States
  • 9236
    New York, New York 10065, United States
  • 9264
    Portland, Oregon 97213, United States
  • 7122
    Pittsburgh, Pennsylvania 15232, United States
  • 4107
    Chattanooga, Tennessee 37404, United States
  • 3000
    Nashville, Tennessee 37203, United States
  • 9003
    Dallas, Texas 75390, United States
  • 9117
    Houston, Texas 77030, United States
  • 9538
    Webster, Texas 77598, United States
  • 9112
    Fairfax, Virginia 22031, United States
  • 9173
    Milwaukee, Wisconsin 53226, United States
  • 9500
    Copenhagen, Denmark
  • 9501
    Bordeau, 33000, France
  • 9525
    Lille, 59000, France
  • 9373
    Lyon, 69008, France
  • 9512
    Poitiers, 86021, France
  • 9476
    Rennes, 44229, France
  • 9496
    Barcelona, 08028, Spain
  • 9363
    Barcelona, 08035, Spain
  • 9508
    Barcelona, 08036, Spain
  • 9429
    Madrid, 28007, Spain
  • 9495
    Madrid, 28040, Spain
  • 9383
    Madrid, 28041, Spain
  • 9382
    Madrid, 28050, Spain
  • 9510
    Valencia, 46010, Spain
09

References and documents

Publications

  • Erika Paige Hamilton, Manish R. Patel, Jordi Rodon, David S. Hong, Alison M. Schram, Pasi A. Janne, Patricia LoRusso, Jasgit C. Sachdev, Sai Hong Ou, Elizabeth A Buck, Matthew O'Connor, Nigel Waters, Karsten Witt, Carl Cook. Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies. J Clin Oncol 38: 2020 (suppl; abstr TPS3665)

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Sep 2022, 32 months.

Results were first posted in Apr 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2019
First posted
Dec 24, 2019
StartActual
Dec 19, 2019
Primary completionActual
Sep 2, 2022
CompletionActual
Sep 16, 2022
Results first posted
Apr 17, 2025
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04209465
Lead sponsor
Black Diamond Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Dec 19, 2019
Primary completion
Sep 2, 2022
Completion
Sep 16, 2022
Results posted
Apr 17, 2025
Last update
Apr 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion